ArticleClinical immunology (Orlando, Fla.)2018

Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.

James D Lord et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.